Continuing : Actualité Continuing en direct - P3 | Bourse Reflex
Accueil > Tags > Continuing

  • Toutes les actualités en rapport avec « Continuing »

05/04 18:00 Continuing - 2016 Annual Results

05/04 07:30 Continuing - Sequana - 2016 Full-Year Results

29/03 18:00 Continuing - Results in line with our Bright2020 strategic plan

28/03 18:45 Continuing - 2016 Annual Results - Revenue increased by 8.2% and EBITDA rose by 8.7%

24/03 18:00 Continuing - With a net profit of 2.8 million euros in 2016, FUTUREN confirms its profitability and demonstrates the strength of its fundamentals

22/03 07:00 Continuing - 2016 full year results : Strong improvement of profitability

22/03 07:00 Continuing - FULL YEAR RESULTS : Good 2nd semester - Operating income up 58%

03/03 07:00 Continuing - ECA Group awarded contracts to equip 680 aircrafts with Emergency Locator Transmitters (ELTs)

02/03 18:30 Continuing - Stabilization of activity: half-yearly turnover of EUR 5.3 million for 2016-2017

27/02 07:00 Continuing - ECA Group awarded a contract by an Asian MOD for degaussing and UAV IT180 based magnetic ranging system

23/02 14:30 Continuing - Le Groupe La Poste - 2016 Annual results

23/02 07:00 Continuing - Revenue target met: EUR 112.5 million, 6.9% growth

25/01 18:00 Continuing - 2016 RENTAL REVENUES

09/11 18:40 Continuing - 2016 9-MONTH TURNOVER

08/11 18:00 Continuing - 2016 3rd quarter results on track with the Bright2020 strategic plan roadmap

24/10 17:45 Continuing - SES-imagotag 9-month sales: EUR 137m (+77%)

17/10 18:00 Continuing - Positive net profit in H1 2006 - Good agronomic performance on 2016 harvest - Gross profit down by EUR 3 million as a result of winter crops - Reduction in administrative and financial costs

13/10 18:00 Continuing - Quantum Genomics announces 2016 first-half financial results and first nine months business update

29/09 18:00 Continuing - 2016 FIRST HALF RESULTS : IMPROVEMENT IN OPERATING PERFORMANCE AND POSITIVE OUTLOOK

29/09 17:45 Continuing - Quantum Genomics reports positive top-line results from Phase IIa trial of QGC001 in hypertension